We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cancer Cells Detected Before They Form Metastases

By LabMedica International staff writers
Posted on 06 Dec 2015
A versatile microarray-based platform has been developed that is able to capture single target cells from large background populations as analyses of rare events occurring at extremely low frequencies in body fluids are still challenging.

Single cancer cells migrate with blood flow through the body before they settle in new tissue and in this way, metastases may be formed, even after the main tumor was treated successfully. More...
It is difficult to detect cancer cells in the blood at an early stage as about one malignant cell is encountered per billion of healthy cells.

Scientists at the Karlsruhe Institute of Technology (Germany) and their colleagues fabricated the device by means of polymer pen lithography, a surface is provided with a microscopically small structure using a plastic die. The target cells adhere to these structures. The blood sample to be investigated is injected into a flat microchannel that crosses the platform. As a maximum number of target cells are to contact the array, a fishbone-shaped structure at the top of the channel stirs up the passing liquid.

In order to underline the feasibility of the presented system in the clinical settings, a series of blood samples from nine breast and one colon cancer patient was analyzed. Samples from healthy individuals were used as negative controls. Prior to pumping the blood sample through the microfluidic device, circulating tumor cells (CTC’s) were pre-enriched by size filtration using the Parsortix System (ANGLE plc; Guilford, UK) using 4 mL of blood per patient mainly to extract red blood cells and to reduce the number of leukocytes. Cells larger than 10 μm in diameter were captured by the Parsortix system, harvested, and exposed to an antibody cocktail of biotinylated anti-EpCAM and anti-HER2 antibodies.

CTCs were discovered in six out of 10 blood samples using the micropattern platform with a range from 0.75 to 2 CTCs/mL. Four samples were deemed negative since both CellSearch (Janssen Diagnostics, LLC; South Raritan, NJ, USA) and the microarray approach were not able to find any CTCs. In three of the remaining six blood samples CellSearch found more CTCs than captured by the new system, range from 3.7to 7.6 CTCs/mL by CellSearch compared to 1.25 to 2 CTCs/mL by the micropattern platform. Two blood samples from patients were even tested positive by the novel device, whereas CellSearch was negative.

Michael Hirtz, ScD, a professor and senior author of the study said, “With our method, we reach a very high hit rate: more than 85% of the extracted cells really are cancer cells, In addition, we can sample suspicious cells undamaged and study them in more detail. While the tumor cells dock to the prepared locations according to the key-lock principle, the remaining cells are simply washed away.” The study was published on October 23, 2015, in the journal Scientific Reports.

Related Links:

Karlsruhe Institute of Technology 
ANGLE plc 
Janssen Diagnostics 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.